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Abstract
The host lymphatic network represents an important conduit for pathogen dissemination.
Indeed, the lethal human pathogen group A streptococcus has a predilection to induce
pathology in the lymphatic system and draining lymph nodes, however the underlying basis
and subsequent consequences for disease outcome are currently unknown. Here we report
that the hyaluronan capsule of group A streptococci is a crucial virulence determinant for
lymphatic tropism in vivo, and further, we identify the lymphatic vessel endothelial receptor-
1 as the critical host receptor for capsular hyaluronan in the lymphatic system. Interference
with this interaction in vivo impeded bacterial dissemination to local draining lymph nodes
and, in the case of a hyper-encapsulated M18 strain, redirected streptococcal entry into the
blood circulation, suggesting a pivotal role in the manifestation of streptococcal infections.
Our results reveal a novel function for bacterial capsular polysaccharide in directing lym-
phatic tropism, with potential implications for disease pathology.
Author Summary
Pathogens are known to invade the host not only via the systemic circulation but also via
the lymphatic network, however the mechanisms underlying the latter route and the con-
sequences for disease outcome have not been well studied. The important human patho-
gen, group A streptococcus, is responsible for a number of clinical syndromes affecting
both the lymphatic vessels and draining lymph nodes, such as lymphangitis and lymphad-
enitis. How such pathologies are orchestrated, and their significance in the development of
serious infection are currently unknown. In this study, we show that the hyaluronan cap-
sule secreted by group A streptococcus is critical for bacterial spread to draining lymph
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nodes, and we demonstrate that this occurs as a result of a specific interaction with the
lymphatic vessel endothelial receptor-1. Genetic deletion or functional blockade of this
receptor prevented streptococcal transit to draining lymph nodes in a murine model of
infection, which in turn enhanced bacterial spread into the blood circulation. Together
these results define a novel interaction between the group A streptococcal capsule and the
lymphatic endothelial receptor-1 as a critical axis in the establishment of lymphatic tro-
pism for this pathogen, with clear implications for disease severity in the host.
Introduction
Lymphatic dissemination of intracellular bacteria and viruses is a well characterized mecha-
nism of pathogenic invasion in the host, which occurs independently of transit through blood
[1–3]. In contrast, exploitation of lymphatics by extracellular bacterial pathogens has received
scant attention, despite clear clinical evidence that such pathogens can induce pathology within
the lymphatic system [4,5].
Group A streptococcus (GAS) is one such important, exclusively human, extracellular path-
ogen. Pathology in the host is initiated by breach of mucosal surfaces and subsequent tissue
destruction, resulting in a diverse disease spectrum spanning the superficial (pharyngitis, pyo-
derma) to the systemic (necrotizing fasciitis, toxic shock syndrome) as well as subsequent post-
infection immune sequelae (rheumatic fever) [6]. Combined, these manifestations of GAS dis-
ease account for the 4th highest mortality rate amongst bacterial pathogens [7].
The onset of invasive bacterial disease is dependent on the appropriately timed expression
of an arsenal of virulence factors which facilitate pathogen dissemination within the host.
The group A streptococci produce over 40 virulence factors, of which the hyaluronan (HA;
(GlcNAcβ1–4-GlcUA)n) capsule [8] expressed by almost all serotypes is critical in defense
against neutrophil-mediated opsonophagocytosis [9]. Elaboration of this capsule further con-
tributes to GAS pathogenesis by facilitating colonization of the host through adhesive interac-
tions between HA and its well characterized receptor, CD44, in pharyngeal epithelium [10,11].
This interaction results in bacterial translocation and subsequent invasion of host tissue via the
paracellular route [12]. We and others have previously shown that GAS have a particular abil-
ity to disseminate from a focus of infection to locally draining lymph nodes [13,14], a feature
that, experimentally, has been associated with systemic dissemination. Clinically, GAS has
been associated with lymphatic pathologies such as lymphadenitis and lymphangitis [4,5]. At
present however, the host factors underlying this apparent lymph tropism and lymphoid tissue
dissemination are completely unknown.
In addition to CD44, a number of other HA binding proteins are expressed in the human
host [15,16]. Lymphatic vessel endothelial receptor (LYVE)-1 is a member of the HA binding
Link protein superfamily that bears 41% amino acid sequence similarity to CD44 [16]. LYVE-1
is almost exclusively expressed in lymph vessels and lymph node sinuses, a system where CD44
is completely absent, and has been implicated in binding of HA from interstitial matrix and in
HA-mediated leukocyte trafficking [16, 17]. However, the propensity for HA-producing patho-
gens to hijack this pathway as a means of lymphatic tropism has not been explored.
In this work, we provide the first evidence to implicate the HA capsule as a critical bacterial
determinant of GAS lymphoid tropism. We further demonstrate that a specific adhesive inter-
action between capsular HA and LYVE-1 is pivotal for GAS dissemination to draining lymph
nodes in vivo, thus defining a novel conduit for GAS translocation, with potentially important
implications for the establishment of systemic disease.
GAS Capsular Hyaluronan Mediates Lymphatic Dissemination via LYVE-1
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Results
Capsular HA is a critical factor for lymphatic trafficking of GAS in vivo
The streptococcal virulence factors which govern bacterial transit to lymph nodes remain
poorly understood. We hypothesized that the HA capsule could play an important role in this
tropism, due to both its anti-phagocytic and adhesive properties. Since the degree of encapsula-
tion varies greatly between GAS serotypes [8], and capsular HA is known to occlude other sur-
face expressed adhesins [18,19], we generated isogenic hyaluronan synthase (hasA) mutant
strains in two important serotypes; the hyper-encapsulated GAS serotype M18, and the lower
density capsule serotype M89, to allow for unambiguous assessment of capsule involvement
(Fig 1A). Importantly, the total ablation of HA capsule expression had no discernible effect on
in vitro bacterial growth rate in either GAS strain (Fig 1A).
Soft tissue infections represent an important GAS disease manifestation, which can readily
be modelled in mice. Such models allow reproducible measurement of spread to locally drain-
ing lymph nodes at early time points following thigh muscle infection, prior to development of
Fig 1. Capsular HA is critical for GAS dissemination to lymphatics. (A) Generation of isogenic acapsular strains of M18 and M89 GAS. Left-right;
Comparison of bacterial growth by optical density (600 nm) and quantification of capsular HA expression expressed as fg of HA per colony forming unit. (B)
Dissemination of wildtype and acapsular GAS in murine soft-tissue infection. Left to right; Bacterial burden (cfu) in ipsilateral lymph node and thigh 3 hours
post-injection (n = 6 mice/group; line depicts median).
doi:10.1371/journal.ppat.1005137.g001
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any severe signs of sepsis. Accordingly, we utilized a murine thigh muscle infection model to
investigate the role of capsular HA in bacterial lymphatic tropism. Significantly, expression of
capsular HA was clearly associated with enhanced bacterial transit to draining lymph nodes in
vivo. Three hours after intra-muscular infection, the bacterial burden in the draining ipsilateral
inguinal lymph node was markedly greater in mice infected with wildtype encapsulated GAS
than that observed for mice infected with isogenic acapsular mutant GAS (Fig 1B). This was
true for both the M18 and M89 isogenic strain pairs. Importantly, there was virtually no spread
to the contralateral node, indicating that bacterial transit to draining lymph node was via affer-
ent lymphatics and not blood circulation.
Loss of capsule expression is known to increase sensitivity of GAS to opsonophagocytic
clearance by neutrophils in a serotype dependent manner, a phenomenon to which M18
strains are particularly sensitive [9]. Consistent with this, we detected a 1.5 log-fold reduction
in bacterial burden at the site of infection in mice infected with isogenic acapsular M18Δcapsule
compared with wildtype M18 (Fig 1B), which corresponded with a significant increase in neu-
trophil-mediated uptake of bacterial cocci in an in vitro opsonophagocytosis assay (S1 Fig).
Despite the observed differences in clearance from muscle between M18 and M18Δcapsule, an
almost three log-fold difference was observed between these isogenic strains upon dissemina-
tion to the draining ipsilateral lymph node (Fig 1B). In the case of serotype M89, loss of capsule
had barely any effect on bacterial clearance from muscle, consistent with in vitro opsonophago-
cytosis data (S1 Fig). Similar to serotype M18 however, this loss of capsule led to a 3-log fold
reduction in transit to the draining inguinal lymph node. These results provide direct evidence
of a new and previously unanticipated role for the GAS HA capsule in directing lymph tropism
and lymphatic spread.
Capsular HA interacts directly with human LYVE-1
Having established a link between HA capsule expression and the capacity of GAS to dissemi-
nate to draining lymph nodes via the lymphatics (Fig 1), we considered the possibility that
the process was mediated by interaction with LYVE-1, the major HA receptor expressed in
human and murine lymphatic vessels, which do not express CD44 [16,20]. We have previously
reported that endogenous LYVE-1 displays only residual levels of constitutive HA binding,
both in vitro and in vivo, due in part to heavy modification with auto-inhibitory sialylated O-
linked glycans [21]. Hence, in preliminary experiments we performed adhesion assays with
recombinant human (hu) and murine (m) LYVE-1 expressed by transfected COS 7 fibroblasts,
a cell type with reduced sialyltransferase activity that permits efficient binding of soluble high
molecular weight HA. Although GAS showed no ability to bind to untransfected COS 7 cells,
encapsulated GAS bound both species of LYVE-1 transfectant avidly, and in a manner that was
specifically inhibited by LYVE-1 blocking mAb (S2 Fig).
To determine whether native sialylated LYVE-1 can support binding of capsular HA we
performed quantitative adhesion experiments with monolayers of primary lymphatic endothe-
lial cells isolated from human dermis (HDLEC), which express abundant levels of the receptor
on the cell surface [22]. Encapsulated GAS bound efficiently to HDLEC, and the adherent
streptococci could be seen to outline the cell borders in a distribution that closely matched that
of LYVE-1 (Fig 2A). Moreover, encapsulated GAS also showed increased binding to HDLEC
that had been engineered to over-express human LYVE-1 by lentivirus-mediated gene trans-
duction (Fig 2B). Binding to native and lentivirus transfected HDLEC was decreased 3 and 8
fold respectively following incubation with LYVE-1 HA-blocking mAbs (Fig 2A and 2B), and
up to 3-fold by competition with a soluble recombinant human LYVE-1 full ectodomain frag-
ment (Fig 2C). Further to this we demonstrated that free high molecular weight HA (>1 x 106
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Da) could compete with encapsulated GAS for LYVE-1 binding in a dose-dependent manner,
resulting in an almost 5-fold reduction in bacterial adhesion to lentivirus transfected HDLEC,
whereas low molecular weight HA (7.5 x 103 Da) could not (Fig 2D). Importantly, addition of a
CD44 HA-blocking mAb had no effect on adhesion (S3 Fig). Together these data indicate that
the interaction between GAS and the lymphatic endothelium was indeed specific and LYVE-1
mediated.
Intriguingly, higher magnification images of HA encapsulated GAS adhering to the surface
of native untransfected HDLEC revealed the individual streptococcal chains to be anchored to
variable sized patches of LYVE-1 tethered by single or multiple cocci (Fig 2E). This suggests
that the configuration of HA within the bacterial capsule, unlike free high molecular weight
HA, can engage the natively sialylated normally quiescent LYVE-1 in lymphatic endothelium
through receptor clustering.
Acapsular GAS do not interact with LYVE-1
The HA capsule constitutes the outermost surface of GAS, and has been demonstrated to mask
both fibronectin binding proteins and M-protein [18,19,23]. Indeed, ablation of capsular HA
can enhance GAS adhesion to a variety of cell types [19], likely due to the subsequent exposure
of addtional bacterial surface proteins, able to interact with host receptors. Consistent with
this, isogenic acapsular GAS displayed enhanced adhesion to both native and LYVE-1 super-
tranfected HDLEC when compared with parental encapsulated strains (S4 Fig), as has been
described previously for other primary human cells [11]. In stark contrast to the preference
shown by HA encapsulated GAS for adherence at endothelial junctions, acapsular cocci aggre-
gated randomly over the endothelial cell bodies, and in a manner that was wholly independent
of LYVE-1 adhesion (S4 Fig). The observed clumping may well result from increased GAS-
GAS interaction upon loss of capsule and the interaction with LECs is most likely mediated by
integrins as described previously for the analogous interaction of non-encapsulated GAS with
epithelial cells [11].
HA encapsulated GAS bind murine lymphatic endothelium
The structures of human and murine LYVE-1 are very similar, and as such we hypothesized
that capsular HA would be sufficient to mediate specific interactions between GAS and native
murine LYVE-1. We assessed this by performing adhesion experiments with monolayers of
primary lymphatic endothelial cells isolated from murine dermis (MDLEC), which express
native LYVE-1 on the cell surface [22]. In common with HDLECs, MDLECs were able to sup-
port binding of encapsulated M18 GAS via the LYVE-1 receptor, as demonstrated by inhibition
of this interaction by inclusion of a specific murine LYVE-1 HA blocking mAb (Fig 3). Similar
to HDLECs, acapsular GAS exhibited clumping and HA-independent adhesion that did not
involve LYVE-1 binding. These results, from both human and murine primary cells firmly
Fig 2. Human LYVE-1mediates GAS adhesion to HDLEC via capsular HA. A-D: Adhesion of
encapsulated M18 GAS untransfected and LYVE-1 lentivirus-transfected HDLECs as indicated above each
panel. (A and B) Left to right; numbers of adherent GAS were determined by quantitative culture and
representative fluorescence microscopy of adherent GAS (30 min incubation) in the presence of control mAb
or LYVE-1 blocking mAb. Scale bars (20 μm). (C) Dose-dependent inhibition of GAS adhesion to HDLEC by
a soluble human LYVE-1 ectodomain fragment. (D) Dose-dependent inhibition of GAS adhesion to lentivirus
transfected HDLECs in the presence of high (HMWHA, solid line) and low (LMWHA, dashed line) molecular
weight HA. (A-D: n = 4, data represent mean+/-SD) (MannWhitney U;* = p<0.05). (E) High resolution
confocal microscopy of M18 GAS following infection of HDLEC. Scale bars (10 μm). Red = LYVE-1,
green = GAS, blue = nuclei. Arrows indicate encapsulated GAS adhering to clusters of LYVE-1.
doi:10.1371/journal.ppat.1005137.g002
GAS Capsular Hyaluronan Mediates Lymphatic Dissemination via LYVE-1
PLOS Pathogens | DOI:10.1371/journal.ppat.1005137 September 9, 2015 6 / 19
establish LYVE-1 as a specific lymphatic endothelial adhesion receptor for HA encapsulated
GAS in vitro.
In order to visualize lymph-borne dissemination of GAS in vivo, mice were infected intra-
dermally in the ear pinna, and confocal microscopy of whole mount sections was utilized to
image bacterial translocation through surrounding lymphatic vessels to the cervical lymph
node draining the site of infection (Fig 4A–4C). Although few images captured bacteria within
the lumen of LYVE-1+ dermal lymph vessels, we could nevertheless observe that GAS were
concentrated in LYVE-1 rich regions, particularly the paracortical regions that receives afferent
lymph from the ear and adjacent dermis (Fig 4D and 4E).
GAS translocation to draining lymph nodes is impaired in LYVE-1
deficient mice
Having shown that the HA capsule is critical for lymphatic dissemination of GAS in the mouse
and identified LYVE-1 as the main adhesion receptor for capsular GAS in primary HDLEC
and MDLEC, we next determined whether LYVE-1 plays a role in GAS dissemination in vivo.
Accordingly, to explore the consequences of total LYVE-1 deletion on the course of lymph-
borne GAS infection we measured streptococcal transit to draining lymph nodes in constitutive
LYVE-1 -/- mice. As previously reported, these mice have no obvious developmental defects,
and have apparently normal lymphatic architecture, fluid clearance and immune function [24].
Following infection via an intra-muscular route, the dissemination of encapsulated M18
GAS was compared between LYVE-1-/- mice and age and sex matched wildtype controls by
quantitative culture. Importantly no difference was observed in bacterial burden at the site of
infection (Fig 5A). However, considerably fewer viable streptococci were recovered from the
draining ipsilateral inguinal lymph nodes of LYVE-1-/- mice compared with wildtype mice (Fig
5B), consistent with a functional role for LYVE-1 in streptococcal uptake and / or nodal transit
through lymphatic vessels. Interestingly, there was a corresponding rise in the number of bacte-
ria recovered from the blood of LYVE-1-/- animals compared with wildtype (Fig 5C and 5D).
Fig 3. Murine LYVE-1 mediates GAS adhesion to MDLEC via capsular HA. Adhesion of M18 GAS to MDLECs. Left to right; numbers of adherent GAS
were determined by quantitative culture (n = 4; Data represent mean+/-SD) (MannWhitney U;* = p<0.05) and representative fluorescence microscopy of
adherent GAS (30 min incubation) in the presence of control mAb or LYVE-1 blocking mAb. Scale bars (20 μm). Red = LYVE-1, green = GAS, blue = nuclei.
Arrows indicate encapsulated GAS adhering to clusters of LYVE-1.
doi:10.1371/journal.ppat.1005137.g003
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This suggests HA-encapsulated M18 GAS can switch to the systemic circulation when access
to the lymphatics is impeded.
In order to visualize the location of M18 GAS in the lymph nodes draining the site of infec-
tion, the same intra-muscular thigh infection model was used, and inguinal lymph nodes from
both wildtype C57Bl/6 and LYVE-1-/- were dissected and sectioned at the 3 hour time-point.
Hyper-encapsulated M18 GAS were readily visible in 3/5 of the inguinal lymph nodes resected
from infected wildtype mice (Fig 5E–5G), consistent with the results of quantitative culture
experiments (Fig 5B). Moreover, while discrete clumps of streptococci could be seen in contact
with LYVE-1+ sinuses within these nodes, the bacteria were particularly prominent in the para-
cortical regions (Fig 5G). Importantly, when lymph nodes from LYVE-1-/- mice were imaged
for comparison, these in all cases (0/4) contained very few bacteria (Fig 5H) and hardly any
were detectable within the paracortical region (Fig 5I). These findings further underline the
functional importance of LYVE-1 for lymphatic dissemination of encapsulated M18 GAS and
support the conclusion that LYVE-1 may regulate the initial entry of bacteria to the afferent
lymphatic vessels.
Functional blockade of LYVE-1 in mice impairs GAS dissemination to
draining lymph nodes
Finally, we explored the consequences of LYVE-1 functional blockade in a mouse model of soft
tissue infection, with pre-administration of either LYVE-1 HA blocking mAb or control immu-
noglobulin. Dissemination of M18 GAS to the draining ipsilateral inguinal lymph node and
persistence of bacteria within the thigh muscle injection site were quantified three hours post-
infection. There was no difference in bacterial burden at the site of infection at this time point
(Fig 6A), however quantification of bacteria recovered from the ipsilateral lymph node revealed
a ten-fold reduction in GAS dissemination following pre-treatment with LYVE-1 mAb (Fig
6B). A similar result was also observed in mice pre-treated with LYVE-1 mAb following infec-
tion with M89 GAS (S5 Fig), confirming the same key role for LYVE-1 in the translocation of
encapsulated GAS to draining lymph nodes indicated from the studies carried out with LYVE-
1-/- mice. Furthermore, in common with LYVE-1-/- mice (Fig 5B), the reduction in bacterial
burden in the draining lymph node of mice infected with M18 GAS was accompanied by a rise
in bacterial burden in spleen (Fig 6C), and blood in LYVE-1 mAb pre-treated mice (Fig 6D).
This effect was not seen in mice infected with M89 GAS and therefore may be specific to M18
GAS.
In order to better understand the influence of the M18 GAS LYVE-1 interaction on disease
outcome and severity, we assessed the impact of LYVE-1 functional blockade on the induction
of sepsis in mice following intra-muscular bacterial challenge over a 24 hour period (S6 Fig).
Consistent with the results obtained at the 3 hour time point, LYVE-1 mAb blockade led to an
almost ten-fold reduction in the number of bacteria recovered from the draining ipsilateral
lymph node compared with IgG treated controls (S6 Fig). This was again coupled with an
increase in bacterial dissemination into the blood circulation and spleen and, additionally at
this time point, the liver (S6 Fig). In order to predict how this would impact on disease
Fig 4. Trafficking of GAS visualized in dermal lymphatic vessels and draining cervical lymph nodes of the mouse ear pinna. A-C: Confocal
microscopic images of murine ear skin 6–24 hours after local intradermal inoculation. (A) Low magnification images of lymphatic vessels in skin and
surrounding infected tissue 24 hours post infection (scale bar 20 μm). (B) 3D rendered images and (C) orthogonal views of the same z-stacks at 6 hours
post infection. Arrows indicate individual streptococci interacting with LYVE-1 dense regions of lymphatic vessel endothelium (scale bar 5 μm). D-E:
Epifluorescence microscopic images of frozen sections of draining cervical nodes 6 hours post infection at low power (100X magnification)(D) and high
power (400X)(E) (Scale bar 50 μm and 20 μm respectively). Red = LYVE-1, green = GAS, blue = nuclei. Arrows indicate encapsulated GAS adhering to
clusters of LYVE-1.
doi:10.1371/journal.ppat.1005137.g004
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outcome, we measured the levels of serum IL-6, a sensitive marker of tissue inflammation.
Although not significantly different, there was nevertheless a clear trend towards increased IL-
6 levels in mice subjected to functional LYVE-1 blockade, (control IgG-treated mean: 1534,
(SD: 372.9); LYVE-1 mAb-treated mean: 1848, (SD: 612.7)). Together these data provide evi-
dence that LYVE-1 mediates interactions between the GAS capsule and lymphatic vessel endo-
thelium that are critical for lymphatic tropism in vivo. Furthermore, in the case of hyper-
encapsulated M18 GAS, this tropism may also limit systemic spread via the blood.
Discussion
The host lymphatic network represents an ideal conduit for extracellular pathogens. Although
recovery of GAS from draining lymph nodes in experimental disease and clinical syndromes
are consistent with lymphatic spread [5], the underlying mechanisms for this potentially criti-
cal process and subsequent impact on disease outcome remain poorly characterized. In this
investigation we demonstrate for the first time that the Gram positive extracellular pathogen,
Group A streptococcus, can rapidly disseminate to draining lymph nodes via the lymphatic
network, and that the process occurs through a specific interaction between the bacterial HA
capsule and the lymphatic endothelial receptor, LYVE-1. We show by means of in vitro binding
studies that expression of LYVE-1 is both necessary and sufficient to support adhesion of
encapsulated GAS in vitro, and provide several lines of evidence indicating that the interaction
between HA capsule and LYVE-1 is critical in vivo for GAS transit to draining lymph nodes.
This was in stark contrast to isogenic acapsular GAS, which, although able to adhere to both
Fig 5. Genetic deletion of LYVE-1 impairs GAS dissemination to draining lymph nodes.Dissemination of M18GAS in murine soft-tissue infection in
constitutive LYVE-1-/- mice (n = 7/group). Numbers of GAS recovered at site of infection (A), ipsilateral draining LN (B), spleen (C) and blood (D) 3 hours post-
infection. Lines depict median values in each case (MannWhitney U;* = p<0.05, ** = p<0.01). (E-I) Confocal micrographs of frozen sections of representative
draining inguinal lymph nodes from wildtype (n = 5) (E-G) and LYVE-1-/- (n = 4) (H and I) mice that were resected 3 hours post infection. Original magnification
was 100X (E and H) or 400X (F, G and I). Scale bars are 100, 50, 20, 100 and 50 μm for E, F, G, H and I respectively.
doi:10.1371/journal.ppat.1005137.g005
Fig 6. LYVE-1 functional blockade reduces GAS dissemination to draining lymph nodes. Dissemination of M18 GAS in murine soft-tissue infection
following LYVE-1 mAb blockade (n = 22/group). Quantitative culture of GAS at site of infection (A), ipsilateral draining LN (B), spleen (C) and blood (D) 3
hours post-infection. Lines depict median values in each case (MannWhitney U;* = p<0.05, ** = p<0.01). (Control antibody group: circles indicate isotype
control antibody and triangles indicate polyclonal control IgG).
doi:10.1371/journal.ppat.1005137.g006
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human and murine LECs, did so in a non-specific and LYVE-1 independent manner and dis-
played a reduced ability to disseminate to draining lymph nodes in vivo.
Our studies have demonstrated a clear requirement for capsular HA in the interaction
between GAS and LYVE-1. As documented for many pathogenic bacteria, GAS is known to
vary capsule expression both in vitro and in vivo, a phenomenon known to be regulated by
multiple factors including the key two-component regulatory system CovR/S [25,26]. In addi-
tion to this, capsule expression can be phenotypically fixed by genetic mutation, as exemplified
by the hyper-encapsulated serotype M18, strains of which harbor a premature stop codon in
the CovR/S regulator RocA [8], and acapsular serotypes M4 and M22, which completely lack
the capsule operon [27]. The impact of serotype-specific variation in capsule expression on
GAS adhesion to LYVE-1 and subsequent transit to draining lymph nodes is a subject that
clearly warrants further study. While we report a similar reduction in transit of M18 and M89
GAS to draining lymph nodes following LYVE-1 receptor blockade, an accompanying increase
in dissemination to the blood circulation and distant organs was only seen following M18 GAS
infection, suggesting serotype specific variation in the role of the capsule LYVE-1 interaction
during infection. We speculate that the interaction between M18 GAS and LYVE-1 augments
association with lymphoid tissue and limits the spread to blood, thus providing a possible
explanation for the infrequent association of M18 GAS with invasive disease and closer associa-
tion with rheumatic fever [7].
It has previously been reported that mutations in the global GAS regulator CovR that nor-
mally represses capsule expression, can result in increased GAS dissemination to draining
lymph nodes, a finding that can now be explained by the observations reported herein [28].
Previous data also demonstrate a role for the chemokine-cleaving protease SpyCEP in transit
of GAS to draining lymph nodes, but the mechanism by which this occurs is still unknown
[13]. As such the significance of lymphatic spread on the pathogenesis of individual GAS sero-
types and other streptococcal species clearly warrants further investigation.
It is interesting to consider the extent to which lymphatic access via the LYVE-1:HA axis
might contribute to the pathogenesis of other extracellular bacteria in addition to GAS. Several
streptococcal species such as the zoonotic S. zooepidemicus and animal pathogens S. equi and
S. uberis are known to express capsular HA [29]. Interestingly virulent S. equi displays a
mucoid phenotype similar to that of hyper-encapsulated serotype M18 GAS, and is associated
with the suppurative equine disease “strangles” that affects primarily the lymph nodes [30].
This further implicates the lymphatic system as a major conduit and focus for infection in
domestic animals, possibly through an interaction with equine LYVE-1. Additional bacterial
pathogens such as Bacillus cereus also express a capsule comprised of HA, while the closely
related B. anthracis exhibits a single nucleotide polymorphism which results in a frame-shift
that precludes the expression of HA [31]. One might speculate that such evolutionary loss of
HA expression impairs access to the lymphatic network, resulting in increased transit through
the blood circulation, as reported here, and may even be a critical determinant in the choice
made by pathogens between these different vascular routes for establishing invasive disease.
The observations made herein may well also be applicable to intracellular bacterial pathogens.
It was recently reported that the Gram negative intracellular pathogen Yersinia pestis dissemi-
nates to draining lymph nodes, but that this process may not require an intracellular stage as
previously thought [2]. These data suggest that the extracellular trafficking of pathogenic bacte-
ria via the lymphatics may represent a universal mechanism for regulating systemic dissemina-
tion, in which LYVE-1 and other host receptors may play critical and previously unrecognized
roles. In the case of GAS, the lymphatic tropism of heavily encapsulated bacteria, may act to
restrict spread to the blood.
GAS Capsular Hyaluronan Mediates Lymphatic Dissemination via LYVE-1
PLOS Pathogens | DOI:10.1371/journal.ppat.1005137 September 9, 2015 12 / 19
We have yet to determine exactly how LYVE-1:GAS interactions mediate lymphatic dissem-
ination. The simplest explanation is that they promote streptococcal translocation into the
lumen of lymphatic vessels and establishment of a reservoir in lymphoid tissue, much in the
same way as GAS interactions with CD44 on the epithelial cell surface promote longevity of
nasopharyngeal carriage and GAS persistence in the nasopharynx [10]. This hypothesis is sup-
ported by our observation that relatively few M18 GAS were recovered from lymph nodes
draining the muscle infection site in LYVE-1-/- mice compared with their wildtype counter-
parts. It is also notable that LYVE-1 is most abundant within the button-like junctions of initial
lymphatics where migrating leukocytes enter from the surrounding tissues [32], and where the
receptor may well facilitate their transit through hyaluronan-mediated interactions. Hence, it is
tempting to speculate that HA encapsulated GAS hijack this normal immune mechanism to
mediate their transit into lymphatics and then to draining lymph nodes. Whether some bacte-
ria exit or-re-enter lymphatic vessels before reaching the lymph node is unknown; it seems pos-
sible that the clinical syndrome of lymphangitis could reflect either the presence of GAS in, or
egress from, lymphatic vessels. GAS interaction with LYVE-1 may influence this and any sub-
sequent inflammation.
The observed interaction between GAS and LYVE-1, and subsequent transit to draining
lymph nodes can be regarded as benefitting either the pathogen or the host. It is widely
accepted that the expression of capsular HA protects GAS against opsonization and phagocyto-
sis by host immune cells, providing a mechanism by which encapsulated GAS could subvert
any specialized innate response elicited by infected lymph nodes [33]. Results herein suggest
that interaction with LYVE-1 or transit to lymph nodes, at least in the case of serotype M18
GAS, may prevent spread to the blood, insofar as blockade or genetic deletion of LYVE-1 not
only prevented lymph node infection but promoted emergence in peripheral blood and distant
organs. However, the interaction of GAS HA capsule with LYVE-1 may also provide an adhe-
sive niche for the establishment of a persistent streptococcal reservoir within draining lymph
nodes.
In conclusion, we describe a novel interaction between GAS capsular HA and the lymphatic
endothelial receptor LYVE-1 that provides an important conduit by which encapsulated strep-
tococci can disseminate into the lymphatic vasculature. To our knowledge this represents the
first identification of a molecular mechanism for entry into the lymphatic system by an extra-
cellular pathogen. Moreover, our findings provide a molecular explanation for the clinical
observation that local lymphatic drainage plays a major role in limiting immediate systemic
spread by GAS. The dissemination of extracellular bacteria in lymphatics may have far reach-
ing relevance in the pathogenesis of both acute bacterial infection and post-infection sequelae.
Methods
Ethics statement
Normal donor cells were acquired from an approved sub collection of the Imperial College Tis-
sue Bank. Use of anonymized human tissue was approved through the Oxford Regional Ethics
Committee. In vivo experiments were performed in accordance with the Animals (Scientific
Procedures) Act 1986, with appropriate UK Home Office licenses according to established
institutional guidelines.
GAS strains
Strains M18, M18Δcapsule and M89 [8] were cultured on Columbia blood agar (CBA) or in
Todd Hewitt broth (THB) at 37°C, 5% CO2. Strain M89Δcapsule was constructed by electropora-
tion with pUCMUThasKO (Table 1) as described previously [8].
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Cell culture and transfections
Primary HDLEC and MDLEC were derived from surgically resected human skin tissue and the
skin of BALB/C pups respectively, using mAb MACS bead magnetic selection as described pre-
viously [22]. Purified cells were cultured in EGM-2 MV on gelatin-coated plastic (0.1%, Invi-
trogen). All cell lines were cultured at 37°C, 5% CO2 under humidified conditions and all
experiments performed using confluent cell monolayers. Transfection of COS 7 with full-
length human and mouse LYVE-1 cDNA and super-transfection of HDLEC with human
LYVE-1 cDNA was achieved by lentiviral transduction.
Lentiviral transduction of COS 7 and HDLEC with human and murine
LYVE-1
Coding sequences of lyve-1 were amplified from the appropriate cDNA using pfu Ultra AD
(Agilent) with the following primers:
huLYVE-1–14 MluI F 5’ GCGACGCGTGAAGGGGTAGGCACGATGGCCAGG
huLYVE-1 969  NotI R 5’ CGCGCGGCCGCCTAAACTTCAGCTTCCAGGCATCGCAC
mLYVE-1–14 MluI F 5’ GCGACGCGTGGAGGGATCTGCACAATGCTCCAG
mLYVE-1 957  NotI R 5’ CGCGCGGCCGCCTAAAC TTCAGCTTCTAAGCATCGCAC
The amplified product was cloned into the lentiviral vector pHR Sin, based on the HIV ret-
rovirus. 293T cells cultured in DMEM supplemented with 10% FCS were transiently trans-
fected with pHR Sin plasmids together with pMD.G and p8.91 [34] using Genejuice (Merck,
Darmstadt, Germany) according to the manufacturer’s instructions. Supernatant was harvested
at 72hrs post-transfection and passed through a 0.45 micron filter to remove cell debris before
transferring to COS 7 cells or HDLEC.
Preparation of soluble recombinant human LYVE-1 ectodomains
The extracellular domain of human LYVE-1 (terminating after residue 238) in a 10 x histidine
tag followed by a stop codon was amplified from a plasmid carrying full-length human LYVE-
1 cDNA using the high fidelity polymerase pfu Ultra AD (Agilent). The construct was trans-
fected into CHO cells and a clone with high expression levels was selected (kindly carried out
by Janet Fennelly and Simon Davis; HIU, WIMM, Oxford). His-tagged protein was purified
from culture supernatants using a 5 ml His Trap column (GE Healthcare). Following elution,
the protein was buffer exchanged into PBS.
Capsule quantification
GAS strains were cultured in THB and capsule quantified as described previously [8] using the
hyaluronan DuoSet (R&D).
Table 1. Bacterial strains used in this study.
Strain Plasmid Strain or gene alteration Previously used
M18 - Identical to H566 [8]
M18Δcapsule pUCMUThasKO Capsule locus disruption mutant [8]
M89 - Identical to H395 [8]
M89Δcapsule pUCMUThasKO Capsule locus disruption mutant This study
doi:10.1371/journal.ppat.1005137.t001
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Antibodies
Primary antibodies used were FITC-conjugated rabbit polyclonal anti-group A carbohydrate
(Abcam ab68879. 0.2 mg/ml), goat polyclonal anti-human LYVE-1 (R&D AF2089), and goat
polyclonal anti-mouse LYVE-1 (R&D AF2125). Blocking antibodies mAb20891 (R&D) and
(BRIC235 IBGRL) were used against human LYVE-1 and CD44 respectively and mAb2125
(R&D) and ab25340 (KM201, Abcam) were used against mouse LYVE-1 and CD44 respec-
tively. Blocking antibodies and isotype controls were used at 20 μg/ml.
GAS adhesion assays
HDLECs, MDLECs and COS 7 cells were seeded at 5x105 cells/well and once confluent, pre-
treated with R10 media (RPMI, 10% FCS, L-glutamine) containing either control or blocking
antibodies against LYVE-1 or CD44, high (>950 kDa) or ultralow (4–8 kDa) molecular weight
HA (R&D Systems, UK), or recombinant soluble human LYVE-1 ectodomain for 20 minutes
at room temperature. GAS were cultured on CBA and resuspended in PBS before being inocu-
lated into each well at an MOI of 10. Adhesion assays were carried out following incubation for
30 minutes at 37°C, 5% CO2. Cells were washed 3 times with 1x PBS (Gibco) to remove non-
adherent bacteria and cell-associated bacteria were quantified following lysis of the cell mono-
layer in sterile water. Replica wells of an 8-well chamber slide (Becton-Dickinson) inoculated
with GAS pre-labelled with FITC-conjugated anti group A antibody (Abcam) were counter-
stained with polyclonal anti-human or anti-mouse LYVE-1 antibodies as appropriate and
imaged using a Zeiss Axiovert inverted epi-fluorescence microscope or a Zeiss LSM780 laser
scanning inverted confocal microscope.
Immunofluorescence antibody staining of mouse tissues
C57Bl/6 female mice (n = 3) were infected intra-dermally with 5×107 M18 GAS and whole
mount tissue sections and draining lymph nodes imaged 6 hours post infection. Whole mount
tissue staining was carried out as described previously [2]. Frozen sections of lymph node were
prepared by cryostat and fixed for 5 minutes in ice-cold acetone. Samples were stained with
polyclonal anti-mouse LYVE-1 Ab and FITC-conjugated anti-group A carbohydrate antibody
(Abcam). Whole mount tissue samples were viewed by Zeiss LSM780 confocal microscope,
using either a Plan-Apochromat 10x/0.3DIC M27 (total magnification: 100x) or Plan-Apoc-
hromat 63x/1.4 oil (total magnification: 630x, resolution: 0.24 μm). For frozen lymph node sec-
tions, nuclei were counterstained with DAPI and sections were viewed on a Zeiss Axiovert
S100 microscope equipped with epi-fluorescence.
Murine intra-muscular infection
FVB/n female mice (4–5 weeks old (Charles River, Margate,UK)), C57Bl/6 and C57Bl/6
LYVE-1-/- female mice (originally obtained from Regeneron Pharmaceuticals, USA) were chal-
lenged intra-muscularly with 1×108 GAS, and quantitative endpoints compared at 3 or 24
hours post infection. For LYVE-1 blocking experiments mice were injected intra-peritoneally
with 0.5 mg anti mLYVE-1 mAb2125 (R&D) or control rat IgG (isotype control or polyclonal)
(R&D) 24 hours prior to infection. Mice were euthanized, blood taken by cardiac puncture and
infected thigh muscle, spleen, liver, and left and right inguinal lymph nodes dissected. All
organs were plated to quantify bacterial cfu and systemic dissemination. For imaging of drain-
ing inguinal lymph nodes, wildtype C57Bl/6 and C57Bl/6 LYVE-1-/- mice (n = 3) were chal-
lenged intra-muscularly in both thighs with 1×108 GAS. Three hours post infection lymph
nodes were dissected and processed as described above for draining cervical lymph nodes, then
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stained with anti-mouse LYVE-1 (mAb C1/8), FITC-conjugated group A carbohydrate anti-
body (Abcam), anti-mouse podoplanin (eBioscience, clone eBio8.1.1) or anti-mouse PNAd
(Biolegend, clone MECA79).
Neutrophil phagocytosis assays
GAS pre-labelled with FITC-conjugated group A carbohydrate antibody (Abcam) were assayed
for ability to resist uptake by purified human neutrophils as described previously [35].
Statistics
All statistical analyses were performed with GraphPad Prism 5.0. Comparison of two datasets
was carried out using unpaired Mann-Whitney and three or more data sets were analyzed by
Kruskal-Wallis followed by Dunn's multiple comparison test. A p-value of0.05 was consid-
ered significant.
Supporting Information
S1 Fig. Capsule enhances resistance of M18 but not M89 GAS to neutrophil-mediated
uptake. Phagocytosis of M18 (A) and M89 (B) GAS and isogenic acapsular mutants quantified
as percentage of neutrophils bearing intracellular GAS. (n = 3; Data represent mean+/-SD)
(TIF)
S2 Fig. huLYVE-1 and mLYVE-1 are sufficient for binding of encapsulated GAS to COS 7
cells. (A) Lack of adhesion of M18 GAS (30 min incubation) to control untransfected COS 7
cells. (B) and (C): Binding of M18 GAS (30 min incubation) to COS 7 cells transfected with (B)
huLYVE-1 or (C) mLYVE-1 in the presence of either control mAb (left) or LYVE-1 blocking
mAb (right), demonstrated by immunofluorescence microscopy. Scale bars (20 μm)
Red = LYVE-1, green = GAS, blue = nuclei
(TIF)
S3 Fig. Blocking of CD44 does not impede adhesion of encapsulated GAS to HDLECs.
Adhesion of M18 GAS to HDLECs. Left to right; quantitative culture (n = 3; Data represent
mean+/-SD) and representative fluorescence microscopy of adherent GAS (30 min incubation)
in the presence of control mAb or LYVE-1 blocking mAb. Scale bars (20 μm).
(TIF)
S4 Fig. Acapsular GAS adhere to human and mouse derived LECs independently of LYVE-
1. Adhesion of M18Δcapsule GAS to HDLECs (A), LYVE-1 lentivirus-transfected HDLECs (B)
and MDLECs (C). Left to right; quantitative culture (n = 4; Data represent mean+/-SD) and
representative fluorescence microscopy of adherent GAS (30 min incubation) in the presence
of control mAb or LYVE-1 blocking mAb. Scale bars (20 μm).
(TIF)
S5 Fig. LYVE-1 functional blockade reduces M89 GAS dissemination to draining lymph
nodes. Dissemination of M89 GAS in murine soft-tissue infection following LYVE-1 mAb
blockade (n = 8/group). Numbers of GAS at site of infection (A) and ipsilateral lymph node
(B), were determined by quantitative culture three hours post infection. Lines depict median
values in each case.
(TIF)
S6 Fig. Prolonged LYVE-1 functional blockade re-routes M18 GAS to the blood circulation.
Dissemination of M18 GAS at 24h after onset of murine soft-tissue infection following LYVE-
GAS Capsular Hyaluronan Mediates Lymphatic Dissemination via LYVE-1
PLOS Pathogens | DOI:10.1371/journal.ppat.1005137 September 9, 2015 16 / 19
1 mAb blockade or control (n = 8/group). Numbers of GAS at site of infection (A), ipsilateral
draining LN (B), spleen (C) blood (D) and liver (E) were determined by quantitative culture
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